Office-use compounding in Iowa

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The mechanism, and why it must be published with the verdictMedium confidence

Iowa’s bar rests on a definition plus the inference that naming one thing excludes the others — not on an express "shall not". The definition reaches only product from an outsourcing facility, and the sole compounding permission granted a pharmacy for non-patient-specific supply is the veterinary one.The honest alternative reading is that Iowa is simply silent, and it deserves stating: the express prohibition was rescinded in 2025 and not re-enacted, and two statutes point the other way without being compounding-specific — the wholesale carve-out and a provision permitting a pharmacy to distribute a prescription drug to a practitioner. A reader who prefers "unruled" reaches the same operational answer, because nothing in Iowa law grants the permission and the federal condition is untouched either way.

The whole rule set moved in 2025 — never cite the old chapterHigh confidence

Iowa rescinded its entire pharmacy rule set on 16 July 2025 and replaced it the same day under a different agency number and different chapter numbering. Citations to the old chapters point at rules that no longer exist, and the rescinded set included the express office-use prohibition quoted above.

The label legend was deleted, not replaced in kindHigh confidence

The "For Office Use Only—Not for Resale" legend no longer exists in Iowa law — zero occurrences in the current chapter, against a working control in the same search. What exists now are two different legends serving a different purpose: "NOT FOR REDISTRIBUTION" and "Not for distribution or resale".

Iowa moved in the opposite direction on one point, and it must not be assimilatedHigh confidence

Iowa now permits dispensing from outsourcing-facility office stock for a patient’s home self-administration. It deleted the prohibition deliberately and said so in its adoption preamble. Every other movement recorded in this file runs the other way, which makes this one easy to summarise into the opposite of what it says.

A federal warning letter is conclusive evidence, not merely evidenceHigh confidence

Two Iowa statutes provide that for a federal food-and-drug violation, an FDA warning letter is conclusive evidence of a violation — grounding a fine, suspension or revocation of the Iowa licence. A separate provision compels disclosure of every inspection observation, warning letter and item of FDA correspondence from the preceding five years, at initial application and at every annual renewal.This is the sharpest federal-to-state coupling in the file. Elsewhere a federal breach is something a state board may weigh; in Iowa the letter itself settles the question.

Quantity and the 5% clauseHigh confidence

No cap appears in the rules at all — four separate quantity phrasings return zero across the whole chapter. The single statutory limit is "minimal quantities", undefined. No denominator exists, which cuts both ways: there is no bright line to exceed and none to shelter behind.

Entity or person — split by drug classHigh confidence

For non-controlled drugs the authority runs to the person: the possession-exemption list names exactly two entity types, a licensed pharmacy and a licensed wholesaler, and every other entry is a natural-person profession. For controlled substances an entity may hold the registration, because the statutory definition of practitioner includes an institution and a business registration category exists.

Last change, and three dated aheadHigh confidence

The rule set was replaced on 16 July 2025. A statutory deadline for accessible-label rules falls on 1 January 2027 and those rules do not yet exist — nothing has been filed. A report to the Governor and General Assembly is due 1 January 2028. The whole replacement rule set carries an automatic rescission date of 11 August 2030 printed on the face of every chapter, unless re-adopted before then.

Iowa at a glance

Receiving 503B office stock in Iowa

Iowa uses the literal term for the credential, so it is safe to search for — but the board that issues it now sits inside a different department and its rules moved to a different agency number in 2025, so the paperwork trail is where the confusion lives.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Iowa asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence

An outsourcing facility licence from the Board of Pharmacy, $400 a year, expiring 31 December, per location. The board is now housed within the Department of Inspections, Appeals and Licensing and its rules appear under the new agency number.There is a seam worth knowing: the licensure trigger names only sterile human non-patient-specific product, so a facility compounding non-sterile product only appears to fall outside it on the face of the statute. That is unresolved rather than settled, and a facility in that position should ask rather than assume.

Does your practice need a permit?High confidence

No, and none exists to obtain. Practitioners are exempt from the pharmacy licensure requirement and are separately excluded from limited-distributor licensure, with no entity substitute created anywhere.

Administer vs dispenseHigh confidence

Iowa is unusual in permitting dispensing from outsourcing-facility office stock for a patient’s home self-administration — it removed the bar deliberately. So the administer-versus-dispense line, which constrains a practice in most states in this file, is looser here on the 503B side specifically.

Scheduled (controlled) stockHigh confidence

Yes — a Board of Pharmacy registration at $45 a year, per practitioner AND per stock location, and a second location needs its own registration the moment it holds stock. It is a precondition to the federal registration: the board’s own guidance says the state number is used to apply for the federal one.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• The verdict rests on a definition plus an exclusionary inference rather than on an express prohibition, and the express prohibition that once existed was rescinded in 2025 and not re-enacted. The alternative reading — that Iowa is simply silent — is stated on this page rather than hidden, because it is a reasonable reading of the same text.
• Whether a non-sterile-only outsourcing facility falls inside Iowa’s licensure trigger is unresolved. The trigger names sterile product, and the seam has not been tested.
• A statutory bar on selling or delivering a "new drug" without federal approval carries no compounding carve-out on its face. Whether a federally exempt compounded preparation escapes it is untested and unresearched — flagged here rather than asserted either way.
• The accessible-label rules due by 1 January 2027 do not yet exist, so what they will require of a compounded preparation’s labelling is unknown.
• We searched no case law, attorney-general opinions or disciplinary orders for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.